



EUROPEAN UNION

Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Slovak Republic Slovenia Spain Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Sweden United Kingdom

LATIN AMERICA & THE CARIBBEAN

Antigua and Barbuda Argentina Bahamas Barbados Belize Bolivia Brazil Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Nicaragua Panama Paraguay Peru St. Kitts and Nevis St. Lucia St. Vincent and the Grenadines Suriname Trinidad and Tobago Uruguay Venezuela

SYNTHETIC DRUGS AND NEW PSYCHOACTIVE SUBSTANCES – BUENOS AIRES, 16TH MAY 2017 Juan Carlos Araneda – Tf.jcaraneda@copolad.eu



SEDRONAR (Argentina) · SENAD (Brazil) · SENDA (Chile) · MINJUSTICIA (Colombia) · ICD (Costa Rica) · CND (Cuba) · VLADA (Czech Republic) · CND (Dominican Republic) · STD (Ecuador) · CNA (El Salvador) · GIZ (Germany) · DNII (Honduras) · CONADIC (Mexico) · CONAPRED (Panama) · DEVIDA (Peru) · NBDP (Poland) · SICAD (Portugal) · NAA (Romania) NDC (Trinidad and Tobago) JND (Uruguay) DEVIDA (Peru) ONA (Venezuela)

EMCDDA · CICAD /OAS · PAHO / WHO · AIAMP · IDPC · RIOD



Contents

- Drugs and synthetic drugs, problem contextualization
- Amphetamine-Type Stimulants (ATS): Global and regional situation
- New Psychoactive Substances (NPS): Global and regional situation
- Early Warning Systems (EWS) on NPS
- Legislation on NPS
- Precursors for production of synthetic drugs/NPS
- Synthetic drugs and NPS Future challenges



Global Synthetic Drugs Assessment



www.copolad.eu





- 247 million people used any drugs at least once in 2014.
- 29.5 million people were users with drug related problems.
- 5.2% was the last year prevalence of use.

(5.2% of 15-64 years old population used any drugs at least once during last year)







011

Fuente: Respuestas al cuestionario para los informes anuales. Nota: Porcentaie estimado de adultos (de 15 a 64 años) que consumieron drogas en el año anterior

010

Prevalencia anua (porcentaje)

4

3

49%49 5

ő

8

Tendencias mundiales del número estimado de personas que consumen drogas, 2006-2014



Fuente: Respuestas al cuestionario para los informes anuales Nota: Estimaciones correspondientes a adultos (15 a 64 años), basadas en el consumo en el año anterior

www.copolad.eu





SYNTHETIC DRUGS

- AMPHETAMINE-TYPE STIMULANTS ATS
- OTHER SYNTHETIC DRUGS





Note: Amphetamines include both amphetamine and methamphetamine. Seizures of synthetic NPS refer to synthetic NPS only and do not include seizures of plant-based substances and ketamine.





DRUG TRAFFICKING Amphetamine-type stimulants

- Total number of psychoactive substances globally under control: 244 (as of January 2016)
- Seizures data show most trafficking involved a much lower number of substances
- Most trafficked drugs, according to UNODC/WDR, 2014:
 - Cannabis in its different presentations: 54%
 - Amphetamine-type stimulants: 17%
 - Opiates and coca-related substances: 12% each
 - New psychoactive substances: 3%
- ATS seizures have increased over seven-fold since 1998, which suggests a growth of synthetic stimulants drug trafficking larger than that of traditional plant-based drugs.
- The enhancement of precursors control reduced the amount of "ecstasy" seizures between 2008 and 2011.
- The use of internationally uncontrolled precursors may have had an influence in the number of "ecstasy" seizures for the 2011-2014 period, twice as much as the previous one.

FIG. 21 Breakdown of drug seizure cases reported worldwide, by type of drug, 2014





Source: Responses to the annual report questionnaire.

Note: Information presented in the figure is based on 2.2 million seizure cases reported to UNODC by 63 countries.





Amphetamine-type stimulants - ATS

amphetamine

and

- Amphetamine-type stimulants:
 - ✓ Involve mainly methamphetamine.
- Other substances included:
 - ✓ methcathinone
 - ✓ phencyclidine
 - ✓ ephedrine
 - ✓ pseudoephedrine
 - ✓ methylphenidate
 - \checkmark MDMA or «ecstasy», an amphetamine-type derivate with hallucinogenic properties.
- ATS and opiates are globally among the mostly used substances after Cannabis.
- In recent years, the majority of the annual global ATS seizures involved methamphetamine.
- Since 2009 the annual global seizures of methamphetamine come mostly from Asia and North America.

		* *
ATS	٨	-
is an acronym for		
mphetamine Type Stimulant	5	ALEX
¢		
by allacronyms.com		
		0

Amphetamine T Stimulant





Injecting use of ATS

- Countries in different regions worldwide have notified the injecting use of ATS.
- Americas: The use of injecting methamphetamines and synthetic cathinones have been reported in certain regions of North America.
- **Europa:** The injecting use of synthetic cathinones have been notified, with users injecting heroin and amphetamines as well.
- A study in Hungary, cited by EMCDDA, shows pentedrone as the mainly used substance of the injecting cathinone class. Other reported substances were the stimulants 3,4-Methylenedioxypyrovalerone (MDPV), mephedrone, and 4-Methylethcathinone.
- In recent years in Greece, both low-threshold services and treatment agencies have regularly informed of the use of crystal methamphetamine among injecting opiates users. This practice has been reported particularly on people injecting opiates who come from migrant marginalized communities in Athens.





Amphetamine-type stimulants POLY-CONSUMPTION

- Poly-consumption of drugs is the combined use of opiates and stimulants like cocaine and amphetamines, a common practice widely reported in international studies.
- Since the last decade, the use of amphetamines and methamphetamines have spread in different regions, whereas the number of NPS –which are stimulantsseems to show a steady increase.
- Data on poly-consumption are rarely gathered. Nevertheless, poly-consumption patterns of amphetamines and NPS have been increasingly reported in different regions.







This project is funded by the European Union

Amphetamine-type stimulants CROSS-TOLERANCE

- Drug dependence: Includes craving, deprivation syndrome, and <u>tolerance</u>.
- The "joint use" of drugs may have a cumulative or synergetic effect, which overall enhances the psychoactive experience, with a possible outcome of developing tolerance.
- A linked phenomenon is the "cross-tolerance": pharmacological feature of a drug generally having the same effect on the nervous system as another drug.
- The "cross-tolerance" phenomenon partly explains a behaviour among users of frequent substitution of drugs for those drugs with similar effects.
- Examples of such pattern of drug use include the consumption of:
 - Alcohol with benzodiazepines, cannabis, or cocaine;
 - Combined use of heroin, benzodiazepines, and antihistamines;
 - Alcohol with opioids (methadone, fentanyl, etc.);
 - And use of cocaine and other stimulants, like amphetamine and methamphetamine.









Amphetamine-type stimulants and HIGH RISK SEXUAL CONDUCTS

- Recent studies have found that people injecting stimulants present sexual conducts of high risk and show higher prevalence of HIV than people injecting opiates.
- A study released in 2015 found that people injecting stimulants (cocaine and amphetamines) have more sexual partners and more frequent sexual encounters with occasional partners than people injecting other drugs.
- Additionally, the risk of contracting HIV is 3.6 higher among injecting cocaine users than this drug's non-injecting users, and the risk increases three-fold among people injecting ATS if compared to non-injecting ATS users.







Amphetamine-type stimulants and HIGH RISK SEXUAL CONDUCTS

- <u>Stimulants users</u> report high injecting frequency, compulsive relapse, and higher probability of reporting shared use and reuse of needles and syringes, which may be contaminated.
- The reason of this is the short duration of effects -particularly NPS, which are stimulants-, in comparison to opiates.





the European Union





European Monitoring Centre for Drugs and Drug Addiction

Recent changes in Europe's MDMA/ecstasy market

Results from an EMCDDA trendspotter study April 2016

MDMA Ecstasy-type substances



European Union countries MDMA or "Ecstasy"-type substances



- In recent years, signs of higher amounts of production and availability of MDMA have emerged, due to:
 - Aperture of new online markets
 - Reports of increased use
 - Alerts of MDMA tablets of high doses, as well as tampered tablets
 - Evidence of low but potentially increasing number of hospital admissions due to MDMA
 - Death reports from MDMA in certain countries.

(Source: EMCDDA 2016 report on «Recent changes in the Europe's MDMA/ecstasy market»)





European Union countries MDMA or "Ecstasy"-type substances



- MDMA and local markets of NPS interact seemingly in a limited manner.
 - An example of this is the potential interaction between cathinones -like mephedrone- and MDMA, despite the available evidence seemingly suggesting that <u>NPS regularly are</u> coupled with other drugs instead of replace them, in particular among frequent users.
- Thus, MDMA and ecstasy caplets have been associated to substitutions and sub-products (PMMA).
 - Nevertheless, the situation of tablets sold as ecstasy, while containing any NPS as the main active ingredient instead of MDMA, has been mostly reverted.
 - <u>Since 2011 MDMA has been recovering a</u> <u>central spot in the European drug market as a</u> <u>sought out non adulterated merchandise.</u>





CELAC countries MDMA or "Ecstasy"-type substances



Figura 2. Prevalencia de último año de consumo de éxtasis entre los estudiantes universitarios de países seleccionados, último año disponible



Fuentes: Primera Encuesta Nacional sobre el uso de alcohol, tabaco y otras drogas entre estudiantes universitarios en las 27 capitales de Brasil, SENAD, Brasilia, 2010; GS-CAN, II Estudio Epidemiológico Andino sobre el Consumo de Drogas en la Población Universitaria, informe regional, 2012 (PRADICAN)

Figura 3. Prevalencia de último año de uso de éxtasis entre los estudiantes secundarios de países seleccionados, último año disponible



Fuentes: DAINLAC; CICAD; Informe Mundial sobre Drogas 2013; 'Informe Ejecutivo, IV Estudio Nacional sobre Prevención y Uso de Drogas entre Estudiantes de Secundaria; Presidencia del Consejo de Ministros, Comisión Nacional para el Desarrollo y Vida sin Drogas, Lima, 2012; 'Noveno Estudio Nacional sobre Drogas en la Población Escolar de Chile, 2011, desde el 8vo año de educación básica al 4to año de secundaria', Chile 2012.





www.copolad.eu



* * * * * This project is funded by the European Union

CELAC countries MDMA or "Ecstasy"-type substances



Gráfico 6-13: Percepción de gran riesgo del uso de "éxtasis" frecuentemente en estudiantes secundarios



Gráfico 6-15: Oferta de "éxtasis" en el último año a estudiantes secundarios





www.copolad.eu





Other synthetic drugs







A controlled substance, added to Schedule I of the 1961 Convention

- Fentanyl is a synthetic opioid recently involved in an increasing number of deaths in different countries.
 - Several countries have raised their concern on the matter, especially Estonia, which shows one of the highest rates of deaths in Europe related to drugs and overdoses mainly associated to the use of fentanyl.
- In Canada, at least 655 deaths were linked to fentanyl as a direct cause or as a contribution to those deaths during the 2009-2014 period.
 - Notably increasing the number of deaths in the four major provinces.
- In the United States, more than 700 deaths were linked to the use of fentanyl between late 2013 and late 2014.
 - A concerning issue is heroin being frequently combined with fentanyl before its sale, leading to heroin users being unaware of their use of fentanyl. This situation may be exacerbated by the recent increase of heroin use in the United States.







- Lysergide is a semi-synthetic hallucinogen and one of the most powerful drugs ever known.
 - Its recreational use became popular between 1960 and 1980, is currently less common than in the past.
- LSD is under international control, although some phenethylamines -most of them under no controlare being sold as LSD in different Latin American countries.
- The international common denomination is (+) lysergide. The acronym LSD derives from the German name Lysergsäurediethylamid (Lysergic acid diethylamide).
 - Lysergide belongs to the family of the indolealkylamines, which includes numerous substituted tryptamines like psilocin (found in "magic" mushrooms) and N,N-dimethyltryptamine





Common presentations of doses of LSD on the street are "blotters"

- Absorbent paper sheet printed with distinctive designs and pre-cut edges for easy tear-up in small squares (typically 7 mm), each one containing a single dose.
- Each sheet typically contains 100 or more doses.
- These units usually show colourful designs of cartoons, geometric and abstract motives.
- LSD is less commonly seen as small tablets ('microdots') 2-3 mm in diameter, as thin gel squares ('window pane') or as capsules.
- Some solutions of LSD in water or alcohol may been found occasionally.
- LSD in solution is sensitive to light, but more stable in units of dosage.















- Ketamine is tightly related to the internationally controlled drug named phencyclidine (known as PCP or "angel dust") included in Schedule II of the 1971 Convention.
 - Phencyclidine was researched as an intravenous anaesthetic in the 1950's, and later recalled due to unwanted effects, like hallucinations and delusions.
- After the recall of phencyclidine, ketamine was synthesized as anaesthetic in 1962, patented in Belgium in 1963 and in the United States three years later.
 - In the early '70s, ketamine was traded as a medical alternative to phencyclidine.

KETAMINE

This project is funded by the European Union

- The use of ketamine as a NPS stems from the '80s and '90s.
- After several considerations, a WHO Expert Committee on Drug Dependence has concluded that it is not recommended to list ketamine as an international controlled substance.
 - Internationally, ketamine was subject to a series of risk evaluations. The WHO Expert Committee on Drug Dependence pre-checked ketamine in 2003 and made a critical review in 2006.
 - After examining the available information, the Committee reached the conclusion that the information was insufficient to justify its incorporation as a controlled substance. It requested as well an updated version of the critical examination that would be presented at the Commission meeting in 2012. In that meeting, the Committee concluded not being appropriate to put ketamine under international control.







- With regard to the European Union, the increasing concern on the use of ketamine as NPS led to a risk assessment in 2000 within the framework of joint action on new synthetic drugs.
- The <u>European Commission</u> concluded that it was not appropriate to introduce control measures and <u>recommended an increased monitoring of ketamine use.</u>
- Ketamine is a dissociative anaesthetic agent, mainly used in veterinary practice.
- Aside its pharmaceutical use, ketamine is frequently sold as "ecstasy" in the illicit ATS's markets.
- Streets names include "K", Special K, cat Valium, among others.
- In high doses, ketamine may cause states similar to dreaming and hallucinations; in even higher doses, ketamine may lead to delirium and amnesia.











Buying DRUGS over the "dark web"

- The dark web includes content that is circulating over encrypted nets or darknets; it makes use of the World Wide Web, but requires special programs or access authorization.
- The purchase of drugs over the Internet, in particular over the "dark web", may have increased during the last years.
 - This trend poses concerns about the potential of the "dark web" to attract new populations of users, easing the access to drugs in an environment
 - -although illegal- that prevents users from the direct contact with criminals and police authorities.
- As the "dark web" cannot be accessed through the typical search on the web, buyers and sellers get access through The Onion Router (TOR), for securely hidden identities.
- Products are usually paid with bitcoins or other crypto-currency, and often delivered via postal services.





Source: Global Drug Survey 2015 (www.globaldrugsurvey.com).

Note: Proportion of survey respondents who bought each drug on the "dark net" among participants in the Global Drug Survey between November and December 2014.



Buying DRUGS over the "dark web"

- Different operations leading by EUROPOL have achieve the complete or partial closure of some important nets. Nevertheless, when one market closes, the most trusted next one tends to absorb the most part of the displaced business.
 - According to an online survey of 2015, purchasing via this net presents certain "advantages" to the buyers, so that it is used even by people who bought or used drugs never before.
 - The survey showed that about 4% of dark web users had never used any drugs before their access via the "dark net".
- In the same way, 30% of people who acquired drugs via the "dark web" reported the use of a wider range of drugs than before starting to purchase over this net.



www.copolad.eu







Source: Global Drug Survey 2015 (www.globaldrugsurvey.com).

Note: The figure shows the proportion of people participating in the Global Drug Survey who bought drugs via the "dark net" between November and December 2014, ^a Based on the replies of fewer than 600 respondents. ^b Regional results show the national (and subnational) results weighted by population.





NEW PSYCHOACTIVE SUBSTANCES-NPS

• General aspects and the scope of the problem



PUBLIC HEARING Proposal for a regulation of the European Parliament and of the Council New Psychoactive Substances

27 November 2013 | JDE 51 | 9.30 a.m. - 1 p.m.

EESC | Jacques Delors Building | 99, rue Belliard | 1040 Brussels

uropean Economic and Social Committe

www.copolad.eu





What are New Psychoactive Substances?

- They are not controlled under any international Conventions on drugs
- Available just recently
- Linked to serious health risks
- Mirror the effects of traditional drugs













What are New Psychoactive Substances?



*Substances in black are already under control, and substances in red have been recommended to international control by the WHO Expert Committee on Drug Dependence

www.copolad.eu





Operational recommendations from 2016 UNGASS for NPS and ATS







DRUG TRAFFICKING New psychoactive substances

- The increase in trafficking has extended even more in the NPS group in recent years.
- Seizures of NPS represented:
 - ✓ 0.1% in 1998
 - ✓ 1% in 2009
 - ✓ 3% in 2014 (surpassing seizures of ecstasy: 2%).
- Seizures of NPS increased fifteen times between 1998 and 2014 (excluding plant-based NPS like khat –Catha edulis- and kratom –Mitragyna speciosa-.
- Globally, ketamine and synthetic cannabinoids became the most seized NPS.
 - ✓ Ketamine seizures 1998-2008: Annual average of 3 tons.
 - ✓ Ketamine seizures 2009-2014: Annual average of 10 tons.



Source: Responses to the annual report questionnaire. Note: Based on information from 120 countries.





NEW PSYCHOACTIVE SUBSTANCES - NPS

 Regional and national situation



New Psychoactive Substances in Europe





Prioritization of NPS: Monitoring emergence, prevalence, and persistence



www.copolad.eu



Monitoring the new psychoactive substances in the European Union



Multisectoral Cooperation

•In recent years, the EMCDDA has become more active in the monitoring of new substances not included in any United Nations conventions, but still pose health and social risks to communities.

•A <u>specific legal instrument adopted by the Council of the</u> <u>European Union in 2005</u> allows institutions and EU member states to take action on the new and potentially dangerous narcotic and psychotropic drugs (plant-based and synthetic) that emerge at the European drug scene.

•It has gained an enhanced capacity to detect and to put the new trends under control.

•Under the Council Decision, the EMCDDA and EUROPOL, with the cooperation of their own networks, and the European Medicines Agency (EMA) play a central roll in the detection of new psychoactive substances by assessing their features and preparing the potential control measures.



www.emcdda.eu.int





Monitoring the new psychoactive substances



A 3-step approach

The Council Decision states the need of a «quick action from the EU member States» in view of the particular dangers the new psychoactive substances pose.

In order to ease this process, an approach in three stages is established, which involves :

in the European Union

- 1. Information exchange/early warning
- 2. Risks assessment
- 3. Decision making

Step 1 – Information exchange / early warning:

Once a new psychoactive substance has been detected in the European drug scene, the member States ensure that any data on production, trafficking, and use of the drug is delivered to the EMCDDA and EUROPOL through the Reitox national focal points and the EUROPOL national units (ENU). The information is shared with the European Commission and the EMA as well. Finally, if EMCDDA and EUROPOL consider the gathered information on a new psychoactive worth active monitoring, a joint report is presented to the EU Council, the Commission and EMA. Based on it, a further decision is made regarding the start of a risk assessment procedure.

Step 2 – Risk assessment:

Following the request of at least the fourth of the members or that of the European Commission, the Council by simple majority may choose to start a risk assessment procedure. The EMCDDA'S Scientific Committee –including additional experts from the member States, the European Commission, EUROPOL, and EMA- assess the potential health and social risks of the newly identified drug and the consequences of its control. It follows a report with the risk assessment for review of the Commission and the Council.

Step 3 – Decisions making: At the initiative of the European Commission or a member State, following the report of the risks assessment, the Council may make the decision by qualified majority voting and adopt a position about a drug and the control measures. Measures of control and legal sanctions in UE's member states are taken according to the national legislations, in complying at the same time with the United Nations Conventions. The Council Decision do not impede member States to unilaterally introduce national control measures they deemed appropriate once a new substance has been detected.



A three step approach

The ASSESSMENTS ENCODE The ASSESSMENTS The ASSESSMENTS The Assessment of the Assessments The Assessment of the Asses

Council Decision 2005/387/JHA: a three-step process



Information exchange/Early-warning

Risk assessment



Decision-making





Monitoring the new psychoactive substances in the Americas



- There is no specific legal instrument from agencies the likes of the Organization of American States, enabling organizations and member States their action on potentially dangerous NPS.
- Nevertheless, official recommendations do exist, adopted within the framework of the Group of Experts on Chemical Substances and Pharmaceutical Products of CICAD/OAS.
- Additionally, the countries meet the decisions of the United Nations Commission on Narcotic Drugs regarding NPS.
- Overall, CELAC countries are in a different stage regarding NPS, if compared with the advances of the United States and Canada in that matter.
- Nonetheless, certain countries from CELAC have moved forward with enhanced monitoring systems that include NPS, the implementation of early warning systems and changes to legislation on drugs in order to add NPS.





the European Union

Monitoring the new psychoactive substances in the Americas



130 0AS - CICAD

CHAPTER 6: A M P H E T A M I N E - T Y P E S T I M U L A N T S

Introduction

Amphetamine-type stimulants (ATS) are a group of substances that include synthetic stimulants such as amphetamine, methamphetamine, ecstasy-type substances^{tim} (such as MDMA, MDA, MDE/MDBA and their analogues), hildhy obtained or falsified prescription medications that contain these substances, and other stimulants such as methathinone and 2C4.⁴⁴

According to the World Drug Report (UNODC, 2014). ATS are the psychoactive substances most used worldwise after manijuena. It was estimated in 2012 that the number of ATS users was 34.4 million for the amphetamine class alone, and 18.7 million users of estab-type substances, while there were 177.6 million users of manijuena, 38 million users of opiolos, 16 million users of ropites, and 17 million user of occeine.

Amphetamines group

The amphetamines group inleades both amphetamine and methamphetamine. Although some amphetamine are produced for medical purposes, most are distributed litegally and produced litlicity in clandestine laboratories.

Methamphetamine are the ATS most widely produced and used. They are a central nervous system stimulant commonly known as "speed", "meth" and "thak". These terms generally refer to the crystalline form of the drug, which can be smoked as "ice", "crystal", "crank" or "glass". It is a white, bitter-tasting, odoriess powder or crystal that is easily soluble in water and alcohol.

The substances in the amphetamines group were originally compounded at the end of the nineteenth century, and solid without medical prescription as neasi decongestants beginning in 1933. When used in similar doses to amphetamine, methamphetamine reach the brain in larger amounts than amphetamine, which makes them a more powerful centural nervous system timulum, those effects of ongest duration.

Both amphetamine and methamphetamine are under international control, and both are on Schedule II of the Convention on Psychotropic Substances of 1971.

North America has had a large and growing market for ATS for a number of years. Manufacture of methamphetamine in particular in Mexico and the United States appears to have grown significantly and coroling to the United States, large volumes of the orag set brought in the tocurity as contraband from Mexico. Nevever, the use of methamphetamine has remained at relatively low and stable levels thus far thoughout the subregion.

^{xer} Given the wide variety of drugs sold on the market as "ecstasy" but after chemical analysis are shown to contain little or no MDMA, this report will use the word "ecstasy" or "ecstasy-hype substances" interchangeably to refer to these drugs. 148 0 AS - CICAD

CHAPTER 7: NEW PSYCHOACTIVE SUBSTANCES AND OTHER EMERGING DRUGS IN THE REGION

NEW PSYCHOACTIVE SUBSTANCES

In recent years, the lifek drug market has seen the appearance of a number of new substances that often have chemical and/or pharmacological properties similar to internationally controlled substances. Their variety has news these greater than it is now.

These new psychoactive substances (INPS) have been termed "designer drugs", "tegal highs", "herbal highs", "bath safts", "research chemicals" and "asonatory respents". In an effort to carrily the language, UNODC uses any the term mer synchroactive substances, which are defined as : "substances of pause, alther in a pure form or a preparation, that are not controlled by the 1982. Single Convention on Norcoic Drugs or the Convention on Psychotropic Substances that are not immed on the pause of the truth of the substances and "new" does not meessarily refer to new inventions, a number of NS' were first synthesise forty years ago, but rether means that they are substances that have appeared recently on the market and that have not been scheduled in the UI Convention.

NPS mimic the effects of controlled substances⁶

Many new psychoactive substances on the market contain chemical products that have structural and/or pharmecological properties similar to the substances under international control and are designed to mimic them.

For example, synthetic cannabinoids, which include the JWH series (such as JWH-018), are compounds that mimic THC (delta-9-tetrahydrocannabinol), which is the principal psychoactive compound in marijuana.

Synthetic cathinones, which include substances like mephedrone, methylone and MDPV, may produce stimulant and empathogenic effects similar to amphetamine, including MDMA.

Phenethylamines include substances such as the 2C series (such as 2C-I) and NBOMe compounds (such as 23)-NBOMe), which produce effects that range from stimulant to hallucinogenic. Some substances in this group are already under international control through the Convention on Psychotropic Substances of 1971, but many of them are still not cheduled.

Tryptamines and their derivatives that have been reported as IVPS are indoleaklylamine molecules. While some tryptamines of natural origin are neurotransmitters (for example, scrotonin, melatonin and bufotenin), most are found as psychoactive hallucinogens in plants, muchrooms and animals (for example, N,Ndimethylriptamin (BMT) psilocylin, and S-methony-N/L-Methylriptamine's (Med-G-MT) (13-).

Inter-American Drug Abuse Control Commission – CICAD Secretariat for Multidimensional Security Organization of American States – OAS



Report on Drug Use in the Americas

2015





NEW PSYCHOACTIVE SUBSTANCES IN NORTH AMERICA



Figure 7-1: Past year prevalence of NPS use in United States 12th grade students, 2011-2014







Graph 7-2: Past month prevalence of New Psychoactive Substances by grouped grades, grades 7-12, Canada, 2012-2013^{xxxvi}







New psychoactive substances in Central and South America

Lifetime prevalence of ketamine use in secondary school surveys





Lifetime prevalence of plant-based substances use in general population surveys

Lifetime prevalence of ketamine use in general population surveys





Source: Drug survey in General Population, Colombia, 2013

www.copolad.eu

Source: Survey for OID/CICAD reports





The most reported new psychoactive substances in Latin America Phenethylamine and synthetic cannabinoids

	Nº cases	Substance Groups	Period
Argentina	30	7	2012-2013
Brazil	22	7	2008-2014
Chile	24	6	2009-2014
Colombia	30	2	2008-2014
Costa Rica	17	4	2009-2013
Ecuador	1	1	2011
México	28	8	2008-2014
Panama	2	2	2011-2013
Peru	2	1	2014
Uruguay	1	1	2009
Total reports	157		

- From 2008 to 2014: 157 reports of NPS
- 54 phenethylamines, 26 synthetic cannabinoids, 24 piperazines, 18 synthetic cathinones, 16 hallucinogenic drugs, 11 plant-based substances, 2 tryptamines, 2 aminoindanes, and 4 other substances.
- Mexico reported NPS of each category, while Argentina and Brazil in seven.

www.copolad.eu



NEW PSYCHOACTIVE SUBSTANCES - NPS

• Early Warning Systems - EWS





Early-warning system on new psychoactive substances

EUROPOL

Operating guidelines



New psychoactive substances in Europe

An update from the EU Early Warning System March 2015



www.copolad.eu





Early Warning System: Users and needs

- International organizations the likes of EMCDDA, CND, the WHO Expert Committee on Drug Dependence, INCB, are all the reference and background for discussion and decision making on trends, maps, terminology, effects, dangers of NPS.
- <u>National experts, politicians, and decision-</u> <u>makers</u>: Data on trends analysis, legal aspects, etc.
- <u>Laboratories</u>: Identification of different types of NPS, analysis methodologies, scientific names, etc.











Review of NPS for international planning

- The UNODC's early warning system contributes to the identification of NPS towards a short listing for international review, taking into account such criteria as geographical prevalence and persistence of NPS.
- Impact: The discussion on international NPS control is centred on a manageable number of substances (higher prevalence, persistence and danger).



the European Union



IMPROVEMENTS IN THE EARLY WARNING SYSTEMS OF Latin American countries



www.copolad.eu





Future challenges for the *Early Warning Systems on NPS*







- Guarantee a constant flow of data on NPS from a broad range of sources (links to national and regional agencies).
- Gather information in a more systematic manner on risks and dangers (pharmacological and toxicological information).
- Support the inclusion of the scheduled NPS (under control) within the different international mechanisms of data gathering, such as ARQ.
- Satisfy demand coming from laboratories and law enforcement towards an improvement in their capacities for detection and identification of NPS.



the European Union



NEW PSYCHOACTIVE SUBSTANCES - NPS

• Risks and challenges







Understanding effects as a step towards understanding markets, trends, and health risks

Classification of over 600 NPS by pharmacological effect







NPS: The public health dimension

Seized products containing mixed new psychoactive substances

Synthetc cannabinoids	Phenetylamines	Phenetylamines	Synthetic cathinones	
•AM-2201 •XLR-11 •Cannabis	•25B-NBOMe •25C-NBOMe •2C-C •2C-B	•4-MA •Amphetamine	Pentedrone Cocaine	What is in the blotters, tablets,?
Synthetc cannabinoids	Synthetc cannabinoids	Piperazines	Synthetic cathinones	
 AKB48 JWH-122 JWH-210 JWH-250 MDPV 	• AM2201 • 5-MeO-DALT	• TFMPP • pFPP • Lidocaine	•3-MMC •3,4-DMMC •alpha-PVP •AMT •MPA •Caffeine	
Under international control at Different chemical NPS substa Pharmaceutical product Adulterants	t time of seizure ance group		March 2016 - Poland - March	NODC Early Warning Advisory New Psychoactive Substances - Poland: "Mocarz" intoxications now linked to synthetic cannabinoid MDMB-CHMICA 2016. In July 2015, Poland registered a large outbreak of intoxications (including at least 3 fatal cases) caused by the use of a NPS as "Mocarz". The product, a herbal mixture containing frequently changing synthetic cannabinoids, has been sold on the Polish market
	augetiennaire 2011		since at least 201 22, <u>5F-PB-22</u> , an	10. Samples serzed arter the outpreak of intoxications revealed to contain various synthetic cannabinoids including <u>UR-144, XLR-11, BE</u> id <u>MDMB-CHMICA</u> . However, no substance had been analytically confirmed so far as the cause of the intoxications/deaths.

Source: UNODC NPS questionnaire 2014

An article newly published in Forensic Science International describes the analysis of one of the fatal cases, whereby the victim died from multiple organ failure after four days of hospitalization. The provided evidence demonstrates the presence of MDMB-CHMICA in ante- and post-mortem blood and internal organs. The study clearly designates MDMB-CHMICA as the main cause of poisoning and concludes that even low doses of this substance might lead to fatal consequences.

www.copolad.eu



Source: Police (Policja) Poland



NPS: The public health dimension





Injecting drug use of synthetic cathinones

UNODC Early Warning Advisory on New Psychoactive Substances

October 2015 - Ireland: Injection of alpha-PVP associated with recently acquired HIV infections among homeless people who inject drugs

DUBLIN, Ireland – October 2015. In February 2015, the Department of Public Health (DPH), Health Service Executive (HSE) in Dublin identified an unexpected increase in cases of acute HIV infection among people who inject drugs (PWID). This increase was associated with the injection of the synthetic cathinone alpha-PVP by so called *chaotic* PWID. Chaotic PWID were defined by clinicians as heroin injectors who were homeless , and if on opioid substitution treatment, required daily attendance at their treatment programme, due to continued use of a variety of other illicit substances in an intensive or chaotic way.

The National Drug Treatment Centre (Dublin) conducted a case-control study among *chaotic* PWID, residing in Dublin and diagnosed with HIV since July 2014, that had been injecting within the previous 12 months. From 38 confirmed and probable cases of HIV infection, 29 persons were homeless and 20 of them provided information on their drug use with 18 reporting to have injected alpha-PVP. The comparison of the case group and the control group showed that the likelihood of recent HIV infection was highest among those who were injecting alpha-PVP daily. As opposed to the control group, individuals in the case group were more likely to have used various drugs including amphetamines and benzodiazepines - in the past 12 months, reused needles and syringes and had sex with PWID partners.



UNODC Early Warning Advisory on New Psychoactive Substances

November 2015 - United Kingdom: Rise of mephedrone and amphetamine injecting in the United Kingdom

LONDON, United Kingdom - November 2015. The findings of a recent update of the report "Shooting Up Infections among people who inject drugs in the UKTrom Public Health England Indicate an Increase in the number of people Injecting stimulants, particularly amphetamine-type stimulants, in the United Kingdom. In the report, concern is expressed about the fact that within five years of the first appearance of mephetorne, around one-in-ten people who inject drugs reported the Injection of this substance. There are also concerns about the injection of mephedrone and other drugs among some sub-groups of MSM (men who have sex with men) during sex, with injecting equipment often shared and condoms not being used.

Among the population surveyed in England, Wales and Northern Ireland, the proportion of people who reported injecting amphetamine-type stimulants as their main drug tripled from 3.9 per cent (38/1,460) in 2004 to 12 per cent (139/1,354) in 2014. The number of people reporting injecting use of amphetamine during the preceding month increased from 18 per cent in 2010 to 24 per cent in 2014. Injecting use of mephedrone during the preceding month was reported by 5.5 per cent (32/1,554) in 2014. Those who had injected mephedrone were younger than those who had not. Mephedrone injecting is a more recent practice which occurs mainly among people who have previously injected other drugs, and among people who have switched from snorting mephedrone.

Increased health problems related to the injection of mephedrone were also reported. In England, Wales and Northern Ireland, those who reported that they had injected mephedrone during the preceding year were more likely to have HUV, to have antibodies to heaptist C virus, and to report having had an injection site infection during the preceding year. These findings suggest that mephedrone injecting may have emerged among higher risk groups with already elevated levels of infection. Those who reported that they had injected amphetamine during the past year were also more likely to have antibodies to heaptist C virus also more likely to have antibodies to heaptist C virus also more likely to have antibodies to heaptist C virus of the injection of the synthetic cathione alpha-PVP by so called *chaotic* PVID was reported earlier this year.



ource: UNAIDS





What are the risks and challenges of NPS?

- Drug users: May not be aware of their use of a NPS instead of previously known drugs, leading to a potential overdose, serious health effects, unknown physiological effects.
- Health services: May not be aware of the broad range of NPS currently in the market, their pharmacology and toxicology, how to identify them, how to bring the right help in emergency cases.
- National laboratories of drugs: May not be in condition to identify the broad range of NPS already available to users (inexistence of standard chemical analyses).
- Law enforcement: May lack the means to detect NPS with the traditional methods.
- Legal systems: May not be able to provide the necessary tools for legal interventions (the NPS are not controlled under international Conventions).

March 2016 - Poland: "Mocarz" intoxications now linked to synthetic c

Poland - March 2016. In July 2015, Poland registered a large outbreak of intoxications (includir herbal mixture containing frequently changing synthetic cannabinoids, has been sold on the Polic various synthetic cannabinoids including UR-144, SUR-11, Be-22, ST-BPAC-22, and NDMB-CHNICA.

An article newly published in Forensic Science International describes the analysis of one of the provided evidence demonstrates the presence of MDMB-CHMICA in ante- and post-mortem bloo concludes that even low does of this substance might lead to fatal consequences.



Source: Police (Policia) Poland

December 2015 - United Kingdom: Treatment demand for NPS doubles

LONDON, United Kingdom - December 2015. Public Health England released i 2015. In addition to alcohol and drug treatment presentations, the number of in number of different substances typically used by people in bars and nightclubs,

The number of individuals presenting to treatment for a club drug or NPS more 2,024 in 2014-15. Conversely, the number of individuals citting "ecstasy has far creased availability and the time it takes recording practice changes to embed having been fully implemented by all treatment providers at the beginning of the second secon

The data was collected through the NDTMS and is used by national and local go

Trends in number of new presentations to treatment citing club drug use





NHS

England

Public Health

England

IUSTICE

Stherapeutic

NPS in prisons



Scotland | Rova

Download our FREE

Weird News

Sport - Technology Money Travel Motoring

Celebs -

iPlayer

TV Rac

< Share 📑 💟 🗠 🖹

TV & Film

mobile and tablet apps >

Inexpensive, powerful, undetectable



www.copolad.eu





Profile of NPS users in the United Kingdom

- 0,7% of adults used NPS during last year.
- 1.1% of males used NPS during last year by comparison to 0.4% of females.
- <u>113,000 (3.6%) of 16-24 years old males used NPS during last year, nearly half the users of NPS.</u>
- There are different cohorts of NPS users, like those who frequent night clubs, users of other drugs, homeless and vulnerable population, people with same-sex practices, particularly males with same-sex sexual partners.
- Inmates comprise another group of NPS users, which include a range of subcohorts as well.
- The synthetic cannabinoids are the only category of illicit drugs whose consumption among inmates is higher in prisons than that in the community (10% vs 6%).
- Patterns of use are constantly evolving due to cost variables and drug purity, besides changes in its legal status and desired or adverse effects.
- The use of NPS is subject to regional variations and frequently associated to local subcultures.





are being sold in the illicit drug markets

• Police authorities of different South American countries have reported on NPS being sold as "LSD" in the illicit drugs market.

✓ May 2013, the National Police in Chile seized 800 "stamps" believed to contain the hallucinogen LSD, while actually consisting on 25I-NBOMe coming from a shipment trafficked from Spain.

✓ June 2013, the Drug Observatory of Colombia reported via its early warning system (EWS) that substances sold as LSD actually contained two NBOMe compounds: 25B-NBOMe and 25C-NBOMe.

- In general, there is no certainty whether the new substances are replacing other substances under control, either in the long run or the short run, or they are just being used as a complement to the range of already existing drugs, under international regulation.
 - ✓ May 2015, the outcomes of a survey on drug use among university students in Uruguay showed "LSD" as the second most used drug exceeding cocaine.
 - ✓ June 2015, the Drug Observatory of Uruguay reported via its early warning system (EWS) that substances sold as "LSD" actually contained 4-Bromo-2,5-dimethoxyamphetamine (DOB).





Legislation on NPS

The national legislations' answers to changes- since 2009

- Making use of (other) regulations (sometimes controversial) not related to drugs
 - ✓ Criminalization of supply
- Modifying drug legislation
 - Criminalization of supply and/or temporary possession or risk assessment mechanisms
- Introducing new legislation on NPS
 - ✓ Criminalization of supply
 - ✓ Or combinations
- Making use of pharmaceutical legislation
- Making use of legislation on consumer protection



www.copolad.eu





PRECURSORS FOR SYNTHETIC DRUGS PRODUCTION

- Precursors control
- Roll of forensic laboratories
- Need of training and exchange of information in a rapid and timely manner

INTERNATIONAL NARCOTICS CON	TROL BOARD
and chemicals frequently of narcotic drug	Precursors used in the illicit manufacture and psychotropic substances 2016
UNITED NATIONS	EMBARGO Observe release date: Net to be published or to reductate before Itrustage, yakach oost, at 1100 hours (EEI) CAUTION



- Solvents and acids included in Schedule II of the 1988 Convention used to be seized in countries where, as a matter of fact, plant-based drugs were produced: cocaine and heroin.
- Currently, the number of countries reporting chemical substances included in Schedule II has increased.
 - Following the increased size of the tracing and seizure operations of synthetic drugs and the improvement of notification of seized chemical substances in illicit laboratories of certain regions.
- In 2015, a total number of 36 countries and territories informed to INCB the seizures of acids and solvents included in Schedule II, whereas 14 countries reported seizures of alternative chemical substances not included in the Schedule.
 - The majority of the countries reporting substances not included in Schedule II came from South America.
- In 2015 the Governments reported seizures of either different chemical substances not included both in Schedule I or II of the 1988 Convention, that may be used for the production of other narcotic drugs, psychotropic substances, precursors, or substances of illegal use under no international regulation, including some new psychoactive substances.











- The seizures of precursors of fentanyl: 1.5 kg of NPP and 78 kg of ANPP in Canada and the United States, respectively, show signs of the illicit production of fentanyl in North America, as a potential source of supply of a drug responsible for the greatest increase of overdose deaths in both countries in recent years.
- Authorities in the United States have started their efforts towards including both chemical substances to Schedule I of the 1988 Convention
- Authorities in Canada and the United States have detected fentanyl's smuggling from illicit production as well as designer synthetic opioids into their territory.
- The amount of seized drugs and precursors should be assessed based on the power of synthetic opioids, since a number of million doses can be obtained for street sale from 1 kg.
 - NPP: N-fenetil-4-piperidona N-phenethyl-4-piperidone
 - ANPP: 4-anilino-N-fenetil-4-piperidina 4-anilino-N-phenethyl-4-piperidine





*Arrows do not represent specific transportation routes.



- In its annual report on drug regulation, China informed of 118 cases of illicit production of ketamine in 2015, an increase of 12,4% compared to 2014.
- After the inclusion of mephedrone in Schedule II of the 1971 Convention, in effect from November 4, 2015, the INCB have received information about an increasing number of incidents related to precursors of that substance, under no international regulations.
- In 2016, the INCB remained receiving notifications via the PICS system on seizures related to precursors of other new psychoactive substances, like precursors of 2-fluoroamphetamine or 2methamphetamine and those of 4-chloroamphetamine and 4-chloromethamphetamine.
- The United States informed about the disassembling of an illicit phencyclidine laboratory in California in 2015 as well as the seizure of different chemical substances -ethyl ether, sodium bisulphite, and sodium cyanide, among them.
- Since a number of precursors' seizures have international ramifications beyond the country where it actually happened, any related detail counts. It might be the start point of an investigation aimed to the source of the chemical substance and the method of diversion.
- Therefore, the INCB encourages Governments the sharing of any information of relevance for the establishment of practical measures whether via the PICS system or bilaterally within the framework of the Projects Prism and Cohesion.





FUTURE CHALLENGES

- Need of building or improving the monitoring and information exchange systems: Surveys, EWS, etc.
- Challenges for control agencies : Police and customs.
- Need of building new skills: Education and training.
- Challenges for health teams: Detection, reaction, and education.
- Challenges for forensic laboratories: Detection, experience exchanges, coordination.
- Potential alternatives for the existing legislation.





Cooperation Programme on Drug Policies between Latin America and the European Union COPOLAD II - 2017

More resources on ATS/NPS:

http://www.emcdda.europa.eu/topics/pods/synthetic-drug-production http://www.emcdda.europa.eu/publications/drug-profiles/amphetamine http://www.emcdda.europa.eu/publications/drug-profiles/mdma http://www.emcdda.europa.eu/publications/drug-profiles/methamphetamine http://www.emcdda.europa.eu/activities/action-on-new-drugs http://www.emcdda.europa.eu/html.cfm/index6006EN.html http://www.cicad.oas.org/Main/Template.asp?File=/oid/smart/default_spa.asp http://www.unodc.org/unodc/en/scientists/science-and-policy.html https://www.incb.org/incb/es/precursors/index.html

